Dr. Kermani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd
Ste 540
Santa Monica, CA 90404Phone+1 310-582-6350Fax+1 310-582-6352
Summary
- Dr. Tanaz Kermani, MD, is a specialized rheumatologist with expertise in vasculitis. She is a faculty member in the Division of Rheumatology at UCLA in the Santa Monica, CA office. She is an alumna of New York Medical College, class of 2004, and completed her Internal Medicine Residency and Rheumatology Fellowship at the Mayo Clinic College of Medicine and Science in Rochester between 2004 to 2010. Dr. Kermani's expertise extends to the treatment of vasculitides, though she also evaluates and treats all rheumatologic conditions. She has contributed extensively to clinical research with multiple publications and book chapters in vasculitis. She is a fellow of American College of Physicians and the American College of Rheumatology.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Rheumatology, 2007 - 2010
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
- New York Medical CollegeClass of 2004
Certifications & Licensure
- CA State Medical License 2011 - 2025
- MN State Medical License 2005 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 58 citationsClinical Heterogeneity of the VEXAS Syndrome: A Case Series.Matthew J. Koster, Taxiarchis Kourelis, Kaaren K. Reichard, Tanaz A. Kermani, David B. Beck
Mayo Clinic Proceedings. 2021-10-01 - 65 citationsTranslation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.Marcela A Ferrada, Sinisa Savic, Daniela Ospina Cardona, Jason C Collins, Hugh Alessi
Blood. 2022-09-29 - 79 citationsRuxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.Maël Heiblig, Marcela A Ferrada, Matthew J Koster, Thomas Barba, Mathieu Gerfaud-Valentin
Blood. 2022-08-25
Authored Content
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
Press Mentions
- Advocate for Prompt Vasculitis Diagnose & TreatmentAugust 28th, 2018
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: